Boehringer Ingelheim GmbH / Johnson & Johnson Inc
Acquisition of the over-the-counter („OTC“) Zantac anti-ulcerant gastrointestinal products from Johnson & Johnson (J&J).
- Closing post FTC clearance of the acquisition of the U.S. rights to the over-the-counter (“OTC”) Zantac heartburn products from Johnson & Johnson (J&J) for $510m.
- The acquisition agreement between BI and J&J signed on Oct. 12th foresees the transfer to BI all intellectual property including trademarks, advertising and promotional materials, formulae for ingredients, inventories, regulatory filings and approval for all products, customer lists and assignable rights to contracts within the United States and Puerto Rico relating to the Zantac brands and its line extensions.
- Extremely high speed of action in streamlined execution of a win-win acquisition which was transformation for Boehringer Ingelheim’s US Gastrointestinal franchise and enabled Johnson & Johnson to exclude a critical part of the primary transaction which could have impeded its closing due to Antitrust reasons.